Skip to main content

Table 2 Efficacy and safety data from the three trials comparing rivaroxaban with the European enoxaparin dose as thromboprophylaxis following elective total hip or knee replacement surgery [2224]

From: Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants

  10 mg rivaroxaban initiated post-surgery 40 mg enoxaparin initiated 12 h pre-surgery
RECORD1 trial (hip replacement)
Total VTE and all-cause mortality (primary efficacy end-point) 18/1595 (1.1%) 58/1558 (3.7%)
Major bleeding 6/2209 (0.3%) 2/2224 (0.1%)
RECORD2 trial (hip replacement)*
Total VTE and all-cause mortality (primary efficacy end-point) 17/864 (2.0%) 81/869 (9.3%)
Major bleeding 1/1228 (0.08%) 1/1229 (0.08%)
RECORD3 trial (knee replacement)
Total VTE and all-cause mortality (primary efficacy end-point) 79/824 (9.6%) 166/878 (18.9%)
Major bleeding 7/1220 (0.6%) 6/1239 (0.5%)
  1. VTE venous thromboembolism
  2. *In RECORD2, rivaroxaban was given for 31 to 39 days, while enoxaparin was given for 10 to 14 days